![\"Independent](\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2026\/10\/1792805182_584_Independent+Membership+White.png\")
<\/p>\n <\/p>\n
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Membership today.<\/p>\n
Join today<\/a><\/p>\n \n Already a member? An artificial intelligence research lab in California said it has administered a custom AI-designed virus<\/a> into a human patient for the first time as a potential scalable solution to counter antibiotic-resistant superbugs<\/a>.<\/p>\n AI lab Radical Numerics announced the treatment on Tuesday, but it is pending scientific scrutiny<\/a> in the form of a peer-reviewed study.<\/p>\n If verified, the treatment, named Omnii-1, could mark the first time AI-designed bacteriophages<\/a> have been administered to a human patient.<\/p>\n These phages are viruses that specifically infect bacteria. Antibiotic-resistant superbugs <\/a>are projected to cause nearly 40 million deaths by 2050<\/a>.<\/p>\n Under current phage treatment approaches for bacterial infections, researchers undertake a time-consuming search of vast environmental collections of phages to find one that happens to match a patient’s specific infection.<\/p>\n It starts with clinicians extracting a sample of the bacteria causing a patient’s infection to find or design phages that kill the infectious bug.<\/p>\n Key to this challenge is understanding the genetic features of a potential phage that could kill particular bacterial strains.<\/p>\n Phages kill bacteria through a multi-step process in which the virus first binds to specific receptor molecules on the surface of the target bacteria.<\/p>\n They then proceed to enter the bacterial cell to hijack it for their own replication and break it open.<\/p>\n The initial binding of the virus to bacteria is very specific, as a given phage only targets particular strains or species of bacteria.<\/p>\n This specificity is a crucial advantage of phage therapy, which spares beneficial gut microbes that tend to be affected by broad-spectrum antibiotics.<\/p>\n Radical Numerics claims that their AI-driven approach can lead to rapid, on-demand generation of phages that meet patient requirements, accelerating the timeline for treatment.<\/p>\n \u201cIn the world’s first clinical use of AI-designed phages, designs generated by Omnii-1 were administered to a patient with an antibiotic-resistant bacterial infection under an authorised, physician-led compassionate-use pathway,\u201d Radical Numerics wrote in a blog post.<\/p>\n \u201cThis milestone marks an early step toward translating AI-guided genome design into personalised therapies,\u201d it said.<\/p>\n The startup claimed that its AI model is trained on diverse genomic sequences and phage genomes, as well as data on previously measured phage-host interactions.<\/p>\n Learning from this information, the AI could identify, as well as design, candidate phages for specific therapeutic requirements.<\/p>\n \u201cWe synthesise Omnii-1-designed phage variants and measure their recovery and activity across bacterial strains,\u201d the startup said.<\/p>\n Recovery is a measure of a phage’s viability, which says whether an AI-designed viral genome can successfully come to life and replicate in the lab.<\/p>\n \u201cThese experiments help characterise the activity of our variants against target hosts and inform subsequent rounds of modelling and design,\u201d Radical Numerics explained.<\/p>\n The company said its Omnii-1 designs were synthesised and administered to a human patient with an antibiotic-resistant infection who had very few remaining medical options.<\/p>\n But it did not reveal specific details of the treatment\u2019s clinical outcomes, citing patient privacy. <\/p>\n","protected":false},"excerpt":{"rendered":"Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Membership today.…\n","protected":false},"author":2,"featured_media":811941,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[59,102,56,54,55],"class_list":["post-811940","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-gb","tag-health","tag-uk","tag-united-kingdom","tag-unitedkingdom"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/811940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=811940"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/811940\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/811941"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=811940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=811940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=811940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n Log in<\/a>\n <\/p>\n![\"Bacteriophage\"](\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2026\/10\/Bacteriophage.jpeg\")
Bacteriophage (NIAID)<\/p>\n![\"Photo](\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2026\/10\/Photo-of-Phage-G.jpeg\")
Photo of Phage G (Kayla Lenz and Richard Allen White III via Eurekalert)<\/p>\n